Introduction
Flavin-containing monooxygenases (FMOs; EC 1.14.13.8) are present in a wide range of organisms, including bacteria, fungi, plants, invertebrates and vertebrates. In eukaryotes, the enzymes are located in the membranes of the endoplasmic reticulum and catalyze the oxidative metabolism of a broad range of structurally diverse chemicals, including therapeutic drugs, dietary-derived compounds and pesticides [1, 2] . Substrates contain, as the site of oxygenation, a nucleophilic heteroatom, typically nitrogen, sulphur, phosphorus or selenium [3] . FMOs are one of the most important of the non-cytochrome P450 (CYP) enzymes involved in the phase-1 metabolism of drugs. Of 860 drugs surveyed, FMOs contribute to the metabolism of about 5%, catalyzing about 2% of the more than 4,000 oxidoreduction reactions undergone by these drugs [4] . However, as outlined below, this might be an underestimate.
In this review, we focus on the role of FMOs in the metabolism of drugs in human and mouse. We describe the FMO genes and proteins of human and mouse, the catalytic mechanism of FMOs and its significance for the metabolism of drugs.
We outline differences between FMOs and CYPs; discuss factors contributing to potential underestimation of the contribution of FMOs to drug metabolism; summarise the developmental stage-and tissue-specific expression of FMO genes and how this differs between human and mouse; and describe factors that induce or inhibit FMOs. We describe the contribution of FMOs of human and mouse to the metabolism of drugs in vitro and in vivo and how genetic variation of FMOs affects drug metabolism in vitro and in vivo. Finally, we discuss the utility of animal models for FMO-mediated drug metabolism in humans.
FMOs of human and mouse
Humans possess five functional FMO genes, designated FMO1 to FMO5 [5, 6] . 
Catalytic mechanism
Much of our knowledge of the catalytic mechanism and substrate preferences of CYPs oxidize chemicals via sequential one-electron processes and, thus, are more capable of producing reactive, potentially toxic products, some of which can inactivate or inhibit CYPs. In contrast, FMOs oxygenate substrates, at a nucleophilic heteroatom, via a two-electron mechanism that generally produces polar, readily excretable detoxification products. Products of FMO-catalyzed reactions, even those that are relatively reactive, do not inhibit the enzyme, but can sometimes inhibit or inactivate nearby proteins, including CYPs [13, 14] .
Factors leading to possible underestimation of the contribution of FMOs to drug metabolism
Methods by which microsomes are prepared and incubated may have lead to underestimation of the contribution of FMOs to drug metabolism. In the absence of NADPH, FMOs are thermally labile [15] . Consequently, liver perfusion in situ, to remove blood before preparation of microsomes, could reduce FMO activity. adding an NADPH-generating system to the microsomes before preincubation and initiating reactions by addition of substrate [15] .
To distinguish between the contributions of FMOs and CYPs to the metabolism of a drug, incubations can be carried out on microsomes that have been pre-heated at 55 o C in the absence of NADPH, which knocks out FMO activity [15] .
To selectively knock out CYP activities microsomes can be incubated at pH 10, or in the presence of carbon monoxide, high concentrations of non-ionic detergents, an inhibitory antibody to NADPH CYP reductase, or chemical inhibitors of CYPs [15] .
However, some CYP inhibitors, such as SKF525A, are substrates for FMO and, therefore, could act as an alternative substrate competitive inhibitor of FMO. The ability of an FMO to catalyze oxygenation of a particular drug can be confirmed by the use of recombinantly expressed FMO.
Differences in expression of FMO genes between human and mouse
There are distinct differences between human and mouse in the tissue-specific expression of FMOs and in mouse marked gender-specific differences. In humans, expression of the FMO1 gene in liver is switched off at birth [16, 17] . This is in contrast to mouse, in which FMO1 constitutes a major form of the enzyme present in adult liver [18, 19] . Silencing of the FMO1 gene in adult human liver may be due to the presence, upstream of the hepatic promoter P0, of a LINE-1 element that acts as a powerful transcriptional repressor [20] . In extra-hepatic tissues, alternative promoters, P1 and P2, are used [6, 20] . In adult human, FMO1 is present in kidney, its main site of expression [21] [22] [23] , and in small intestine [22] . In adult mouse, Fmo1 is expressed in liver, kidney, lung [19] , white adipose tissue [24] and, to a small extent, in whole brain, in which it is the most highly expressed FMO [19] . In mouse, expression of Fmo1 in liver and lung is greater in females than in males, but in kidney is greater in females [19] .
In both human and mouse, the main site of expression of FMO2 is lung [1, 19, 25] . FMO2 is also present in kidney [1, 19] .
In humans, expression of FMO3 in liver is switched on after birth [17, 21] and continues to increase throughout childhood and adolescence, reaching a maximum in adulthood [17] . FMO3 declines during menstruation [26] but otherwise there is little difference in expression between males and females. In mouse, however, there is a profound gender difference in the expression of Fmo3 [19, 27] . In females, Fmo3 expression is switched on after birth, increases to reach a peak at five weeks of age and is maintained, albeit at a slightly lower level, throughout adulthood; in males, it increases from birth to three weeks of age and is subsequently switched off, being undetectable by five weeks of age.
The FMO4 gene is expressed in several tissues in human and mouse but, with the exception of human pancreas, in all cases the expression is very low [1, 6, 19] .
The gene for FMO5 is expressed in the embryo and in many tissues of fetal and adult human and mouse [6] . In both organisms it is most highly expressed in adult liver and in this organ its abundance is similar to or greater than that of FMO3 [1, 19] .
In humans, FMO5 is highly expressed also in stomach and pancreas [6] and in the small intestine, in which it is the most highly expressed FMO gene [1] . In mouse, it is expressed also in kidney [19] and in small and large intestine, where it is the most highly expressed isoform [28] . In mouse liver and kidney, Fmo5 expression is higher in males than in females [19] .
In mouse liver, mRNAs for FMO1, FMO2, FMO4 and FMO5 are present at birth. Those encoding FMO2 and FMO4 exhibit no significant age-related changes. In contrast, expression of Fmo1 and Fmo5 changes with age, increasing after birth, to reach a peak at five weeks post-partum [19]. As described above, Fmo3 expression exhibits gender-specific age-related changes. With the exception of FMO3 (see above), no equivalent information is available on the effect of age on FMO expression in humans.
Complement of FMOs in major organs involved in drug metabolism
The complement of FMOs present in major sites of drug metabolism, such as liver, kidney, lung and small intestine, differs qualitatively and quantitatively in both human and mouse and there are marked species differences [1, 19] (Table 1 ). In adult human liver, the main FMOs are FMO3 and FMO5, with FMO1 being absent. FMO3 and FMO5 are abundant in female mouse liver, but FMO1 is also present. In adult male mouse liver, FMO1 and FMO5 are present, but FMO3 is absent. In human kidney, the most abundant FMO is FMO1, followed by FMO2. In female mouse kidney, FMO1 is the most abundant isoform, but in male mouse kidney, the abundance of FMO5 is similar to that of FMO1. In human lung, by far the most highly expressed FMO mRNA is that for FMO2. However, as discussed in Section 12, most humans do not produce functional FMO2 from the mRNA. In mouse lung, both FMO1 and FMO2 are expressed [19, 29] . FMO5 is the main isoform present in the small intestine in both human and mouse. suggests that their contribution to drug metabolism might be underestimated.
Regional-specific expression of FMOs
In adult female mouse liver, mRNAs encoding FMO2, FMO3 and FMO4 are expressed in the periportal region, the expression of FMO3 mRNA being far greater than that of FMO2 or FMO4. In contrast, mRNAs encoding FMO1 and FMO5 are expressed primarily in the perivenous region, with a gradient across the acini [19] . In the kidney, expression of all five FMO mRNAs is localized to the distal and proximal tubules and the collecting ducts [19] . FMO1 mRNA was detected also in the glomerulous [19] . In lung, FMO1, FMO2 and FMO5 mRNAs are localized to the endothelial lining of the alveoli and terminal bronchiole [19] . FMO3 mRNA is present only in the terminal bronchiole, and, unlike the situation in liver, in lung this isoform is present in both adult male and female mice [19] .
Little information is available on the regional localization of FMOs in human tissues such as liver and kidney. However, in human skin, an organ that is exposed to numerous chemicals, FMO1, FMO3, FMO4 and FMO5 mRNAs are localized in the epidermis, sebaceous glands and hair follicles [36] .
Induction and inhibition of FMOs
In contrast to CYPs, FMOs are not readily inducible by foreign chemicals. An exception is FMO5, which is inducible in human hepatocytes by rifampicin [37] , in HepG2 cells by hyperforin [38] and in a breast cancer cell line by the synthetic progestin R5020 [39] . In primary hepatocytes isolated from mice there are gender differences in Fmo5 expression in response to some chemicals [40] . In response to progesterone, the abundance of FMO5 mRNA was increased in hepatocytes isolated from female mice, but reduced in cells isolated from males, and rifampicin induced Fmo5 expression to a much greater extent in hepatocytes isolated from female than from male mice. In mouse, the abundance of FMO mRNAs can be influenced by diet S-oxygenation of methimazole, a sulfenic acid, results in a decrease in CYP content [13] .
Drug substrates of FMOs
Of the FMOs, FMO1 has the broadest substrate range, followed by FMO3. FMO1 and FMO3 share some substrates in common, e.g., benzydamine, itopride, N-deacetyl ketoconazole, voriconazole and tamoxifen, but are relatively selective towards others, e.g., FMO1 for chlorpromazine, imipramine and quazepan, FMO3 for procainamide. This is certainly the case for aliphatic tertiary amines, FMOs producing exclusively the N-oxide, whereas CYP-mediated oxidation results in N-dealkylation [59] .
Drugs that are likely to be metabolized exclusively or predominantly by FMOs include benzydamine [60] , itopride [61] , olopatadine [62] , pargyline [5], ranitidine [31, 63] and xanomeline [64] , via N-oxygenation, and albendazole [65] , cimetidine Another factor contributing to the potential underestimation of the contribution of FMOs to the N-oxygenation of drugs containing tertiary amines is that the N-oxides can be retro-reduced to the parent compound by CYPs or other reductases [67] , such as quinone reductase [68] and aldehyde oxidase [69] . The contribution of FMOs to the metabolism of drugs containing secondary amines may also be underestimated. In this case, the initial product of the FMO-catalyzed reaction, an N-hydroxyamine, is converted, via a second oxygenation, to a nitrone, which is hydrolyzed to produce an aldehyde and a hydroxylated primary amine [70] , the latter being enzymatically reduced to a primary amine, the same product as would be produced from the initial secondary amine substrate by a CYP-mediated Ndealkylation [71] .
In addition to drugs, FMOs catalyze the oxygenation of several other foreign chemicals, including the pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (FMO1) [72] , insecticides, such as phorate and disulfoton (FMO2) [73] , and dietary-derived compounds, such as trimethylamine (FMO3) [74, 75] . However, discussion of the involvement of FMOs in the metabolism of non-drug xenobiotics is beyond the scope of this review.
Role of FMOs in endogenous metabolism
Because of charge restrictions, discussed in Section 3, almost all small endogenous nucleophiles are excluded from the active site of FMOs. Exceptions include the biogenic amines tyramine [76] and phenethylamine [77] , which are converted by human FMO3 to the N-oxide, then via a second, stereoselective, N-oxygenation to the trans-oxime. Human FMO3 can also catalyze S-oxygenation of methionine, but, as the KM for the reaction is in the mM range, its physiological relevance is questionable.
Porcine FMO1 can S-oxygenate cysteamine and cysteine S-conjugates, but again, in the latter case the KM is high, casting doubt on its metabolic relevance.
The use of Fmo-knockout mouse lines has revealed that, in addition to contributing to the metabolism of drugs, FMO1 and FMO5 have roles in endogenous metabolism, FMO1 as a regulator of energy balance [24] and FMO5 as a regulator of metabolic aging, acting via pleiotropic effects, including influencing weight gain and plasma concentrations of glucose and cholesterol [78] .
Genetic variants of FMOs and their effect on drug metabolism
Most humans are homozygous for a nonsense mutation of FMO2, c.1414C>T
(p.(Gln472*)) [79] . The resultant allele, FMO2*2A, encodes a truncated polypeptide, FMO2.2A, that lacks 64 amino-acid residues from its carboxy terminus and is catalytically inactive [79] . Thus, in contrast to mouse, most humans do not express The influence of c.769G>A(p.(Val257Met)), a SNP that is common in Asian populations, also is substrate dependent. This is illustrated by its effect on the ability of FMO3 to catalyze the N-oxygenation of the anti-cancer aurora kinase inhibitors danusertib and tozasertib [98] . The variant significantly reduces the N-oxygenation of danusertib, but has no effect on production of tozasertib N-oxide. These segregate into 15 haplotypes. Of these, two markedly decrease transcription in vitro, whereas one increases transcription 8-fold [100] . The effect of the promoterregion SNPs on transcription of the FMO3 gene in vivo is not known.
Drug-drug interactions are thought to be rare for substrates of FMO3 [59] .
However, a study in vitro demonstrated that FMO3-catalyzed N-oxygenation of benzydamine was inhibited by several substrates, including itopride, tozatertib, methimazole and trimethylamine, and S-oxygenation of sulindac sulfide was inhibited by methimazole [101] , but, as discussed in Section 9, the use of methimazole as an inhibitor of FMO activity can be problematic. It is suggested that individuals with reduced FMO3 activity, such as those with the (p.(Glu158Lys;Glu308Gly)) compound variant, might experience unexpected consequences in drug response if exposed to more than one FMO3 substrate. Glu158Lys;Glu308Gly) ) was found to have a reduced capacity for ranitidine Noxygenation [94] . N-oxygenation of ranitidine by FMO3 has been confirmed in vivo The antipsychotic olanzapine is converted in vitro to its N-oxide by FMO3
[109] and, through the action of CYPs, can be hydroxylated or N-demethylated [109, 110] . The N-oxide can be formed also by CYP2D6 in vitro, but olanzapine metabolism in vivo is not influenced by CYP2D6 genotype [111, 112] . Olanzapine Noxide formation in vitro by the FMO3 variant (p.(Glu158Lys;Glu308Gly)) was lower than by the ancestral form, (p.(Glu158;Glu308)) [113] . When the influence of this compound variant was examined in vivo the C/D (median dose-adjusted steady-state serum concentration) of olanzapine N-oxide in patients homozygous for (p.(Glu158Lys;Glu308Gly)) was ~50% lower than in individuals heterozygous or homozygous for the ancestral form, but the variant allele had no effect on the plasma concentration of olanzapine [114] . In a study of Japanese, several genotypes of FMO3 and CYPs were found not to be associated with changes in olanzapine clearance, the conclusion being that the drug is subject to multi-pathway metabolism and if one pathway is less effective others compensate [112] . Variants of FMO1 have been shown to alter olanzapine metabolism. In this case, the non-coding variant FMO1*6, which decreases promoter activity in vitro (see above), was found to increase serum C/Ds in patients [114] .
Itopride, a gastroprokinetic agent, undergoes N-oxygenation through the action of FMO3 in vitro [61] and in vivo [115] and this is considered the major route of metabolism. Chinese individuals homozygous for (p.(Glu158Lys;Glu308Gly)) had higher plasma concentrations of itopride and lower concentrations of the N-oxide than those homozygous for the ancestral form (p.(Glu158;Glu308)) [115] .
The involvement of FMO3 in clozapine N-oxygenation was demonstrated in vitro [116] . A study in vivo found no correlation between clozapine N-oxide production and the (p. 
FMO3 converts nicotine to its N-oxide [49] and, in humans, 4-7% of nicotine
equivalents are excreted as the N-oxide. CYP2A6, however, is the most important contributor to nicotine metabolism and nicotine N-oxide excretion is increased to ~30% of the absorbed nicotine in individuals homozygous for a CYP2A6 deletion [117] . Polymorphisms that influence FMO3 activity would, therefore, be expected to be of greater importance in individuals with compromised CYP2A6 activity.
Mouse models for FMO-mediated drug metabolism
A consequence of the marked differences between human and mouse in expression of FMO1 and FMO3 in adult liver and the lack of functional FMO2 in most humans is that there are distinct differences between the species in the metabolism of drugs in vivo by FMOs. For instance, drug substrates of FMO1 will be metabolized in mouse, but not human, liver; substrates of FMO2 will be metabolized in mouse, but not in the majority of humans; and substrates for FMO3 will be metabolized in liver of humans and female mice, but not of male mice. Therefore, wild-type mouse is not a good animal model for FMO-mediated drug metabolism in humans. However, female mice, because they express FMO3 in adult liver, may be useful as a model for FMO3-mediated metabolism, and, if used in combination with adult male mice, which lack hepatic FMO3, for confirming the participation of FMO3 in metabolism of a drug.
Few studies have directly compared the contribution of FMOs to drug metabolism in vivo in humans and mice. A study of procainamide, using a urinary metabolite profiling approach, concluded that in humans N-oxidation represents a major metabolic route, producing procainamide N-oxide and N-acetyl procainamide N-oxide, whereas in mice this was a minor route [118] . Experiments in vitro confirmed that both FMO3 and FMO1 catalyze oxygenation of procainamide and Nacetyl procainamide, the rates of formation being higher for FMO3. However, the mouse study used adult males and the differences found between human and mouse likely result from the lack of FMO3 in adult male mouse liver. can also help assess the contribution of a FMO protein to the metabolism of a drug that undergoes multi-pathway metabolism in vivo [120] . For instance, the antidepressant imipramine is oxygenated only by FMO1, to produce the N-oxide [119] . Imipramine N-oxide undergoes retroreduction in vivo, thus, quantification of the oxygenated product in plasma or urine can miss or underestimate the contribution of FMO1 to overall metabolism and clearance of the drug. Using an Fmo1-null mouse model, imipramine was shown to cause sedation only in wild-type animals, i.e., those that produced imipramine N-oxide in brain [119] . Adverse behavioural changes, such as tremor, were observed only in mice that lacked FMO1 (the knockout mice), which produced higher amounts in brain of desipramine, a product of CYP-mediated metabolism. ) was used to better mimic the situation in human, with respect to expression of FMOs in lung, and to establish whether a lack of FMO2 influences the metabolism of ethionamide in vivo [122] . The plasma concentration of ethionamide was found to be higher in knockout than in wild-type mice and that of ethionamide S-oxide to be higher in wild-type than in knockout animals, confirming the involvement of FMO2
FMO2 catalyzes the S-oxygenation
in the metabolism of ethionamide. To be effective ethionamide must be taken up by mycobacteria in the lungs and subsequently metabolized, by the bacterial monooxygenase EtaA, to the sulfenic acid, which acts as the therapeutic agent [123] .
Metabolism of ethionamide in the lung by FMO2 to the sulfoxide and, subsequently, to a potentially toxic sulfenic acid, would be expected to reduce drug efficacy, by diminishing the amount of prodrug available for uptake by mycobacteria, and increase harmful side effects.
Conclusions
Five , Fmo2 (-/-) , Fmo4 (-/-) ) express in adult liver FMO3 and FMO5, but no other FMOs, and, thus, for most humans are a good model for FMO-mediated drug metabolism.
Expert opinion
A number of drugs have been identified as substrates for FMOs, some being [64] a metabolite of disulfiram, product is a sulfine; b major metabolite of ketoconazole; c metamphetamine hydroxylamine is further converted by FMO action to a mixture of nitrones, which are subsequently hydrolysed to yield an aldehyde and a hydroxylated primary amine, the latter then being reduced to a primary amine; d active metabolite of esonarimod; e the active metabolite of the prodrug sulindac; f major metabolite of tazarotene. 
